CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2021-09-08
Target enrollment:
Participant gender:
Summary
This is a single center, single arm Phase I study to establish the safety and feasibility of
intravenously administered lentivirally transduced dual PSMA-specific/ TGFβ-resistant CAR
modified autologous T cells (CART-PSMA-TGFβRDN cells) in patients with metastatic castrate
resistant prostate cancer.